Clinical Trial: A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07204964) titled 'A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above' on Oct. 01.

Brief Summary: The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.

Study Start Date: Oct. 10

Study Type: INTERVENTIONAL

Condition: Influenza, Human

Intervention: BIOLOGICAL: Flu mRNA (Formulation B1)

One dose of Flu mRNA (Formulation B1) received intramuscularly.

BIOLOGICAL: Flu mRNA (Formulation B3)

One dose of Flu mR...